Xin Lang Cai Jing·2025-08-25 01:23Group 1 - The core viewpoint of the news highlights the trading performance and financing activities of Junshi Biosciences, indicating a significant level of trading activity and high financing balance [1] - On August 22, Junshi Biosciences experienced a stock price increase of 1.10%, with a total transaction amount of 683 million yuan, and a net financing purchase of 17.69 million yuan [1] - The total financing and securities lending balance for Junshi Biosciences reached 1.273 billion yuan, with the financing balance accounting for 3.60% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs, with 84.18% of its revenue coming from drug sales [2] - For the first quarter of 2025, Junshi Biosciences reported an operating income of 501 million yuan, representing a year-on-year growth of 31.46%, while the net profit attributable to shareholders was -235 million yuan, showing a year-on-year increase of 17.01% [2] - As of March 31, 2025, the number of shareholders of Junshi Biosciences was 29,400, with a slight increase of 0.24% compared to the previous period [2] Group 3 - As of March 31, 2025, among the top ten circulating shareholders of Junshi Biosciences, the Huaxia SSE STAR 50 ETF held 30.25 million shares, a decrease of 5.05 million shares from the previous period [3] - The E Fund SSE STAR 50 ETF held 21.58 million shares, down by 869,200 shares compared to the previous period [3] - Hong Kong Central Clearing Limited increased its holdings to 14.99 million shares, an increase of 152,780 shares from the previous period [3]